Abstract: This study investigated the effect of phloroglucinol combined with ritodrine hydrochloride on serum erythropoietin-producing hepatocyte receptor (Eph) A5, soluble vascular endothelial growth factor receptor-1 (SFlt-1) and placental blood flow indicators (energy ultrasound) in patients with placenta previa. A total of 96 patients with placenta previa were divided into single drug group and combination group according to different treatment plans, 48 cases in each group. The single drug group was given ritodrine hydrochloride, and the combination group was given phloroglucinol combined with ritodrine hydrochloride. The success rate of miscarriage protection, term rate of pregnancy, vaginal bleeding time, prolonged gestational age, drug onset time, 1 min Apgar score, serum alpha-fetoprotein (AFP), creatine kinase (CK), Eph A5, SFlt-1, placental blood flow (energy ultrasound) indexes [vascular flow index (VFI), vascularization index (VI), flow index (FI)] and safety. The success rate of miscarriage preservation and the full-term pregnancy rate in the combination group were higher than that in the single drug group (P＜0.05). The prolongation time of gestational weeks in the combination group was higher than that in the single drug group (P<0.05). After treatment, the levels of serum CK, AFP and sFlt-1 in the combination group were lower than those in the single drug group, and the level of Eph A5 was higher than that in the single drug group (P<0.05). VFI and VI in the combination group were lower than those in the single-drug group after treatment, and there was no significant difference in FI between the two groups (P>0.05). There was no significant difference in the total adverse reaction rate between the two groups (P>0.05). Phloroglucinol combined with ritodrine hydrochloride can improve the therapeutic effect of patients with placenta previa, and can effectively improve placental blood flow and promote embryonic development, decreased SFlt-1 levels, increased Eph A5 levels.

Key words: hallucinogenic, ritodrine hydrochloride, placenta previa, Eph A5, SFlt-1, placental blood flow